BB Biotech AG Publishes Interim Report and Announces Leadership Change

BB Biotech AG has released its interim report as of June 30, 2024, detailing business results for the first half of the year. The company reported a net profit of CHF 173 million for this period, reversing a loss of CHF 267 million in H1 2023. However, the second quarter saw a loss of CHF 87 million, compared to a loss of CHF 13 million in the same quarter last year. This profit reflects the performance of stocks in its portfolio.

A leadership change was also announced. Dr. Daniel Koller, head of the investment management team since 2010, will retire by the end of 2024. Dr. Christian Koch, one of the current deputy heads, will assume the role starting January 1, 2025.